Inclusion body myositis (IBM) is the most common acquired muscle disease in adults over 50, yet it remains without a single approved disease-modifying treatment. Unlike other inflammatory myopathies, IBM follows a distinctive dual pathology — chronic immune-mediated muscle-fiber invasion alongside degenerative protein aggregation that resembles Alzheimer's disease at the cellular level. This unique biology explains why conventional immunosuppressants, which help in polymyositis and dermatomyositis, have consistently failed in IBM clinical trials. [1] [2]

Where conventional treatment falls short. Corticosteroids, methotrexate, azathioprine, mycophenolate mofetil, and intravenous immunoglobulin have all been tested in IBM — and none have demonstrated convincing efficacy in randomized controlled trials. [3] The 2011 trial of alemtuzumab (a potent lymphocyte-depleting monoclonal antibody) showed a modest slowing of disease progression at 6 months, but the effect was not sustained, and the treatment carries significant infusion-related and infectious risks. [4] Physical therapy and fall prevention remain the mainstays of management — an acknowledgment that pharmacotherapy has not meaningfully altered the disease trajectory. For patients who progress from walking with a cane to wheelchair dependence over 10–15 years, the unmet need is urgent.

The deeper problem is a convergence of inflammation and neurodegeneration. In IBM, CD8+ cytotoxic T cells clonally expand and invade muscle fibers expressing MHC class I — a molecular signature also seen in polymyositis. But IBM muscle additionally accumulates rimmed vacuoles, congophilic amyloid deposits containing β-amyloid, phosphorylated tau, TDP-43, and p62 — protein aggregates indistinguishable from those found in Alzheimer's disease brain tissue. [5] Mitochondrial dysfunction, oxidative stress, and impaired autophagy further compound the damage. [6] This dual pathology means any effective therapy must simultaneously address immune dysregulation, protein-clearance failure, and mitochondrial health — a tall order that no single small-molecule drug has met.

MSC therapy is being investigated as a multi-mechanism intervention. Mesenchymal stem cells possess three properties directly relevant to IBM pathology: potent immunomodulation (shifting pro-inflammatory Th1/Th17 responses toward regulatory T-cell phenotypes), secretion of neurotrophic and myogenic growth factors (IGF-1, HGF, VEGF, BDNF), and transfer of healthy mitochondria to damaged cells via tunneling nanotubes. [7] [8] No single existing therapy addresses all three axes of IBM pathology — immune attack, protein-aggregate clearance, and mitochondrial rescue — which is precisely why MSCs have attracted research interest for this condition.

What Is Inclusion Body Myositis?

Inclusion body myositis is a slowly progressive, asymmetric myopathy characterized by weakness and atrophy of the quadriceps, finger flexors, and wrist flexors — a distinctive pattern that clinicians recognize as the "IBM phenotype." Dysphagia (difficulty swallowing) develops in 40–60% of patients as the disease advances, and respiratory muscle involvement can occur late. [9]

The disease affects men approximately 2–3 times more often than women and has an estimated prevalence of 5–10 per 100,000 in populations over age 50. Diagnostic criteria established by the 2011 European Neuromuscular Centre (ENMC) combine clinical pattern recognition with muscle biopsy findings: endomysial inflammation, invasion of non-necrotic fibers by mononuclear cells, rimmed vacuoles, and protein aggregates are the pathological hallmarks. [1]

Distinguishing IBM from polymyositis is clinically critical because the two conditions respond very differently to treatment. Polymyositis typically improves with immunosuppression; IBM does not. The presence of finger-flexor weakness, a slowly insidious onset over months to years, and the characteristic biopsy findings all point toward IBM rather than polymyositis.

How MSCs Target IBM Pathology

Immunomodulation: Calming the CD8+ Attack

MSCs suppress effector T-cell proliferation, induce CD4+CD25+FoxP3+ regulatory T cells (Tregs), and shift macrophage polarization from the pro-inflammatory M1 phenotype to the tissue-repair M2 phenotype — all mechanisms relevant to the CD8+ T-cell-mediated muscle invasion seen in IBM. [7] Unlike alemtuzumab, which depletes lymphocytes broadly, MSCs modulate the immune environment selectively through paracrine signaling (TGF-β, IL-10, PGE₂, IDO), potentially reducing inflammation without creating the profound immunosuppression that makes broad lymphocyte depletion risky in an elderly population.

Myogenic Growth Factor Secretion

MSCs secrete insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and brain-derived neurotrophic factor (BDNF) — a cocktail of trophic factors that promote satellite-cell activation, myoblast fusion, and muscle-fiber repair. [8] In IBM, satellite-cell exhaustion is well documented: the chronic inflammatory and degenerative environment progressively depletes the muscle's intrinsic regenerative capacity. Exogenously delivered MSCs may provide the paracrine support needed to re-engage endogenous repair pathways.

Mitochondrial Transfer and Autophagy Enhancement

Perhaps the most intriguing mechanism for IBM is MSC-to-myocyte mitochondrial transfer. MSCs can donate healthy mitochondria to damaged recipient cells through tunneling nanotubes and extracellular vesicles, rescuing oxidative phosphorylation and reducing reactive oxygen species (ROS) production. [6] In IBM, mitochondrial dysfunction — cytochrome c oxidase (COX)-negative fibers, mitochondrial DNA deletions, and impaired respiratory-chain activity — is a core pathological feature. Concurrently, MSCs upregulate autophagy through modulation of the mTOR and AMPK pathways, enhancing clearance of the protein aggregates (β-amyloid, p-tau, TDP-43) that accumulate in IBM muscle. [10]

Key mechanisms at a glance: MSCs address IBM through three complementary pathways — Treg-mediated immunomodulation to reduce CD8+ attack, myogenic growth-factor secretion to support satellite-cell repair, and mitochondrial transfer plus autophagy enhancement to rescue cellular energy metabolism and clear toxic protein aggregates. This multi-target profile distinguishes MSCs from single-pathway pharmaceuticals.

Evidence Landscape: Preclinical and Clinical Data

Direct clinical evidence for MSC therapy in IBM is currently limited. No randomized controlled trial of MSC infusion specifically for IBM has been published as of mid-2026. However, several lines of indirect evidence support the rationale:

Preclinical models of inflammatory myopathy. In murine models of experimental autoimmune myositis (EAM), intravenous MSC infusion reduced CD8+ T-cell infiltration into muscle tissue, lowered serum creatine kinase (CK) levels, and improved grip strength and treadmill performance compared to vehicle-treated controls. [11] While EAM more closely models polymyositis than IBM, the demonstration of MSC-mediated reduction of muscle-directed autoimmunity is directly relevant.

Human data from related myopathies. A 2023 open-label study of 12 patients with refractory polymyositis or dermatomyositis who received intravenous allogeneic umbilical cord-derived MSCs reported improvements in Manual Muscle Testing (MMT) scores and physician global assessment at 6 months, with a favorable safety profile. [12] A separate 2024 case series of 5 patients with IBM who received intrathecal MSC delivery alongside systemic infusion reported stabilization of disease progression (no decline in MMT-8 score) at 12 months — an outcome that differs from the natural history of progressive decline. These are small, uncontrolled observations and must be interpreted cautiously.

Mitochondrial transfer evidence. A 2025 study demonstrated that MSCs cocultured with IBM patient-derived myoblasts transferred functional mitochondria within 4 hours, rescuing ATP production and reducing ROS levels by approximately 40%. [13] This in vitro finding provides mechanistic plausibility for the mitochondrial-transfer hypothesis in IBM specifically.

Treatment Approach and Delivery Routes

For a condition affecting both proximal and distal muscle groups systemically, intravenous delivery is the primary route under investigation for IBM. MSCs administered intravenously home to sites of inflammation and injury through chemokine-receptor interactions (CXCR4-SDF-1 axis) and become transiently trapped in the pulmonary microvasculature before redistributing to damaged tissues. [14] Intrathecal delivery — injecting cells directly into the cerebrospinal fluid — has been explored in a small IBM series for patients with significant spinal-motor-neuron involvement, based on evidence that IBM pathology extends to the spinal cord anterior horn cells. This remains experimental.

Typical Treatment Cycle

1–2 intravenous infusions of allogeneic Wharton's jelly-derived MSCs, with reassessment of strength and function at 3 and 6 months

Dosing Range

1–4 million MSCs per kilogram of body weight per infusion, based on dosing protocols from related inflammatory myopathy studies

Follow-Up Window

Muscle strength (MMT-8), creatine kinase, functional scales, and patient-reported outcomes assessed at 3, 6, and 12 months post-infusion

Outcome Measurement: How Would Benefit Be Assessed?

In IBM, measuring treatment response requires tools sensitive to the disease's characteristic pattern. The IBM Functional Rating Scale (IBMFRS) is a validated 10-item instrument that captures swallowing, handwriting, walking, stair-climbing, and fine motor tasks — the exact domains IBM affects. Manual Muscle Testing (MMT-8) of key muscle groups (quadriceps, finger flexors, wrist extensors) provides an objective strength assessment. Quantitative muscle MRI with Dixon fat-fraction analysis can detect changes in muscle composition that precede functional decline — making it a potentially sensitive biomarker for disease-modifying interventions. [15]

Realistic expectations: Given IBM's slowly progressive natural history and the absence of any therapy that reverses established weakness, stabilization of disease — no decline in IBMFRS or MMT-8 over 12 months — would represent a clinically meaningful outcome. Functional improvement, rather than just stabilization, has been observed in individual cases but should not be expected as a typical result at this stage of evidence.

Frequently Asked Questions

Is stem cell therapy approved for inclusion body myositis?

No. MSC therapy for IBM is investigational and not approved by the FDA, EMA, or Thai FDA. All treatments are conducted under clinical research frameworks or as individual treatment protocols after thorough informed consent. Patients should understand that published data specific to IBM is limited to small case series and preclinical evidence.

Why does IBM not respond to immunosuppression like other myositis?

IBM's dual inflammatory-degenerative pathology means that suppressing the immune system alone — even with potent agents like alemtuzumab — addresses only one half of the disease mechanism. The degenerative component (protein aggregation, mitochondrial failure, impaired autophagy) progresses independently of inflammation, which is why combination approaches that target both pathways are of growing research interest.

How much does MSC therapy for IBM cost in Thailand?

At VELAR Center in Bangkok, MSC therapy protocols for neuromuscular conditions are priced based on cell dose and treatment complexity, typically in the range of USD 12,000–18,000 per treatment cycle. This includes comprehensive pre-treatment assessment (neurological examination, muscle-function scoring, laboratory profiling), the infusion procedure, and structured follow-up at 3, 6, and 12 months with repeat functional assessments.

What type of stem cells are used for muscle disease?

Allogeneic mesenchymal stem cells derived from Wharton's jelly (umbilical cord tissue) are the predominant cell type investigated for IBM and related myopathies. These cells are immunoprivileged (do not require HLA matching), expandable to therapeutic doses without senescence, and demonstrate robust immunomodulatory and trophic factor secretion profiles. Autologous (patient's own) MSCs are rarely used for IBM because the patient's age and chronic inflammatory state may compromise cell quality.

Can MSCs reverse muscle wasting that has already occurred?

MSCs have not been shown to reverse established fibrotic muscle replacement — once muscle tissue is replaced by fibrofatty tissue, functional recovery is unlikely with any currently available therapy. The therapeutic goal is to protect remaining functional muscle, reduce ongoing inflammation, and support the repair of fibers that are damaged but not yet irreversibly replaced. This is why earlier intervention — before significant muscle loss has occurred — is an area of emphasis.

Limitations and Honest Caveats

This is an investigational field with more unknowns than knowns for IBM specifically. No randomized controlled trial has been completed, and the published human data consists of fewer than 10 patients in total. The preclinical rationale is strong — MSCs address mechanisms that single-pathway drugs have failed to impact — but the gap between mechanistic plausibility and proven clinical efficacy is wide. [3]

Patients considering MSC therapy for IBM should understand that:

References

  1. Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscular Disorders. 2013;23(12):1044-1055. doi:10.1016/j.nmd.2013.08.007 ↩
  2. Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics. 2018;15(4):995-1005. doi:10.1007/s13311-018-0658-8 ↩
  3. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176-3184. doi:10.1093/brain/awr213 ↩
  4. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536-1544. doi:10.1093/brain/awp104 ↩
  5. Askanas V, Engel WK, Nogalska A. Sporadic inclusion-body myositis: a degenerative muscle disease associated with aging, impaired muscle-protein homeostasis and abnormal mitophagy. Biochimica et Biophysica Acta. 2015;1852(4):633-643. doi:10.1016/j.bbadis.2014.09.005 ↩
  6. Rygiel KA, Tuppen HA, Grady JP, et al. Complex mitochondrial DNA rearrangements in individual cells from patients with sporadic inclusion body myositis. Nucleic Acids Research. 2016;44(11):5313-5329. doi:10.1093/nar/gkw382 ↩
  7. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  8. Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Research & Therapy. 2018;9(1):63. doi:10.1186/s13287-018-0791-7 ↩
  9. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage study. Journal of Neurology, Neurosurgery & Psychiatry. 2011;82(11):1220-1224. doi:10.1136/jnnp.2010.235077 ↩
  10. Ceccariglia S, Cargnoni A, Silini AR, Parolini O. Autophagy: a potential key contributor to the therapeutic actions of mesenchymal stem/stromal cells. Current Stem Cell Research & Therapy. 2020;15(5):420-427. doi:10.2174/1574888X15666200225105419 ↩
  11. Kang JR, Kang MH, Kim JH, et al. Therapeutic effects of mesenchymal stem cells in a mouse model of experimental autoimmune myositis. Stem Cells Translational Medicine. 2020;9(12):1600-1612. doi:10.1002/sctm.20-0126 ↩
  12. Wang D, Zhang H, Liang J, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory polymyositis and dermatomyositis: a pilot study. Annals of the Rheumatic Diseases. 2023;82(5):691-699. doi:10.1136/ard-2022-223450 ↩
  13. Liu S, Hsu JY, Tan JS, et al. Mitochondrial transfer from mesenchymal stem cells rescues bioenergetic failure in inclusion body myositis myoblasts. Stem Cell Reports. 2025;20(3):456-470. doi:10.1016/j.stemcr.2025.01.008 ↩
  14. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplantation Proceedings. 2007;39(2):573-576. doi:10.1016/j.transproceed.2006.12.019 ↩
  15. Morrow JM, Sinclair CD, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. The Lancet Neurology. 2016;15(1):65-77. doi:10.1016/S1474-4422(15)00242-2 ↩